Focused Issue on Non-Small Cell Lung Cancer

Posted On 2019-06-25 13:50:25


This focused issue on “Non-Small Cell Lung Cancer” is edited by Dr. Alfredo Addeo, from Oncology Department, University Hospital Geneva, Geneva, Switzerland; and Dr. Giuseppe Banna, from Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy.

Dr. Alfredo Addeo is a senior oncologist at the Geneva University Hospital, Geneva Switzerland. He received his training at the University of Turin (Italy) and completed a MD in oncology at the University school of medicine of Turin (Italy). Dr. Addeo has been working on thoracic malignancies since 2006 at the Geneva University Hospital. He has several publications on international peer-reviewed journal (JCO, Lancet Oncology, Annals of Oncology, Jama Oncology, etc). He is the lead for several translational research projects in his department: his main interests at the moment are liquid biopsy, ctDNA and TMB in thoracic malignancies.

Dr. Giuseppe Banna is a consultant medical oncologist with a clinical and scientific experience mostly focused on thoracic and urological cancer. He is the clinical lead of a division of medical oncology in Catania (Italy) and has the Italian qualification as Associate Professor since 2017. He has been involved in translational and clinical research as the principal or co-investigator in more than 30 sponsored GCP protocols and no-profit clinical studies and participates to national and European cancer research networks (such as the EORTC and ETOP groups).

Focused issue outline:
  1. Preface to this focused issue
    Alfredo Addeo, Oncology Department, University Hospital Geneva, Geneva, Switzerland
    Giuseppe Banna, Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy
  2. Pathology in non-small cell lung cancer: evolving scenario
    Umberto Malapelle, Department of Public Health, University Federico II of Naples, Naples, Italy
  3. NSCLC targetable mutations: present and future
    Sandip P. Patel, Division of Hematology/Oncology, Department of Medicine, Moores Cancer Center, University of California-San Diego, La Jolla, CA, USA
  4. Role of genomics in NSCLC
    Christian Rolfo, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA
  5. CT screening for lung cancer
    Fabrizio Minervini, Lucerna Hospital, Luzern, Switzerland
  6. Optimising Liquid biopsy in NCSCL (Remained to be decided)
    Thierry Nouspikel, Molecular and Genomic Diagnostic Laboratory, Service of Medical Genetics, Department of Genetic Medicine, Laboratory Medicine and Pathology, University Hospitals of Geneva, Geneva, Switzerland
  7. The role of radiotherapy in the evolving treatment scenario of stage III non-small cell lung cancer
    Abhro Chaudhuri, Lincoln County Hospital, Lincoln, UK
  8. Role and room for biomarkers in NSCLC
    Glen J. Weiss, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
  9. SCLC treatment landscape
    Stephen V. Liu, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, 20057, USA
  10. New treatment options in EGFR mutated NSCLC
    Simona Perano, Geneva University Hospital, Geneva, Switzerland
  11. Role of immunotherapy in mesothelioma
    Alex Friedlaender, Department of Oncology, Hôpitaux Universitaires de Genève, 4 Rue Gabrielle Perret-Gentil, 1205, Geneva, Switzerland
  12. How to recognize and manage hyperprogression and pseudo-progression during immune checkpoint blockade
    Francesco Facchinetti, Medical Oncology Unit, University Hospital of Parma, Parma, Italy
  13. From RECIST to immune-RECIST: how to assess disease response to checkpoint inhibitors in clinical practice
    Jessica Menis, Medical Oncology, University of Padua and Veneto Institute of Oncology IOV - IRCCS, Padua, Italy